KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 5 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,463,843 | +45.4% | 124,878 | +29.2% | 0.13% | +36.1% |
| Q4 2023 | $1,695,083 | +77.3% | 96,641 | +75.6% | 0.10% | +59.0% |
| Q3 2023 | $956,166 | +233681.4% | 55,047 | +89.5% | 0.06% | +154.2% |
| Q2 2023 | $409 | -44.8% | 29,045 | -57.8% | 0.02% | -46.7% |
| Q1 2023 | $741 | -37.7% | 68,881 | -13.3% | 0.04% | -38.4% |
| Q4 2022 | $1,190 | -99.9% | 79,419 | +14.5% | 0.07% | +23.7% |
| Q3 2022 | $891,000 | +30.6% | 69,378 | -1.4% | 0.06% | +40.5% |
| Q2 2022 | $682,000 | -3.9% | 70,339 | -1.5% | 0.04% | +10.5% |
| Q1 2022 | $710,000 | -13.7% | 71,384 | +2.1% | 0.04% | -5.0% |
| Q4 2021 | $823,000 | +10.2% | 69,927 | +6.7% | 0.04% | +2.6% |
| Q3 2021 | $747,000 | +24.3% | 65,559 | +52.1% | 0.04% | +21.9% |
| Q2 2021 | $601,000 | – | 43,116 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |